NCT05271370View on ClinicalTrials.gov

An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 29, 2017

Primary Completion Date

December 20, 2022

Study Completion Date

April 10, 2023

Conditions
HIV-1-infection
Interventions
DRUG

PRO 140 350

Pro140 SC injection 350 mg

DRUG

PRO 140 525

525 mg

DRUG

PRO 140 700

700 mg

Trial Locations (1)

94115

Quest Clinical Research, San Francisco

Sponsors

Lead Sponsor

CytoDyn, Inc.
All Listed Sponsors
lead

CytoDyn, Inc.

INDUSTRY

NCT05271370 - An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study | Biotech Hunter | Biotech Hunter